The FDA has approved nivolumab, in combination with certain chemotherapies, for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal…
The FDA has approved pembrolizumab for the treatment of patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) carcinoma.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
R1 margins did not significantly influence OS and RFS after resection compared with R0 margins in patients with GIST, according to results from a retrospective study.